AVRO - AVROBIO inks gene therapy pact with University of Manchester for MPS-II

AVROBIO (AVRO) has entered into an exclusive, license agreement and collaborative research funding agreement with The University of Manchester for an investigational lentiviral gene therapy (AVR-RD-05) for mucopolysaccharidosis type II (MPS II), or Hunter syndrome.The Phase 1/2 trial for Hunter syndrome is expected to commence in 2H of 2021.Under the license agreement, AVROBIO will pay an upfront cash payment and additional milestone payments, as well as mid-single digit percentage royalty on annual net sales of licensed products, to the University.Under the collaborative research funding agreement, AVROBIO will take over the budgeted Phase 1/2 trial costs.Company's other investigational gene therapies are in Phase 1 and Phase 2 trial for Fabry disease, Phase 1/2 trial for cystinosis and a Phase 1/2 trial for Gaucher disease. Also has a preclinical program in Pompe disease.Further details on the new Hunter syndrome program will be discussed at upcoming virtual R&D Day on November 17.

For further details see:

AVROBIO inks gene therapy pact with University of Manchester for MPS-II